donanemab

all catalysts(0)

nothing on the calendar yet

News(7)

• Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
  Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.
  fiercebiotech · 15d ago
• BMS’ neuro renaissance was built on back of Celgene mega-merger
  Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychi…
  biospace · 1mo ago
• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 2mo ago
• Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
  The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
  biopharma_dive · 2mo ago
• STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
  People on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipated
  stat · 4mo ago
• STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
  Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
  stat · 4mo ago
• Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
  A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.
  biopharma_dive · 5mo ago